CYTK

Cytokinetics, Incorporated [CYTK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CYTK Stock Summary

Top 10 Correlated ETFs

CYTK


Top 10 Correlated Stocks

CYTK


In the News

08:01 29 Mar 2024 CYTK

7 Biotech Stocks Ready to Ride the Sector's Resurgence

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.

03:43 29 Mar 2024 CYTK

Cytokinetics: CEO Talks Down Buyout Prospects

Cytokinetics: CEO Talks Down Buyout Prospects

02:25 29 Mar 2024 CYTK

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.

04:00 29 Mar 2024 CYTK

Cytokinetics to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March:

06:11 29 Mar 2024 CYTK

Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to loss of $1.45 per share a year ago.

04:00 29 Mar 2024 CYTK

Cytokinetics to Announce Fourth Quarter Results on February 27, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

09:10 29 Mar 2024 CYTK

3 Biotech Stocks to Buy for the Next Bull Run: February 2024

The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve the quality of life of all human beings.

04:32 29 Mar 2024 CYTK

Cytokinetics (CYTK) Down on Report of Novartis Not Interested

Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.

11:54 29 Mar 2024 CYTK

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Previously recommended "Sell" on Cytokinetics; Aficamten's SEQUOIA-HCM data outperformed expectations, necessitating reevaluation. Aficamten revealed possibly improved efficacy and safety compared to Camzyos, implying that it could become a blockbuster treatment in HCM. CYTK's M&A appeal surged post-data, despite a dip after Novartis cooled acquisition talks; the current market cap suggests upside potential.

05:37 29 Mar 2024 CYTK

Cytokinetics stock plunges as Novartis retreats from merger talks

Cytokinetics stock plunged more than 16% Thursday to $84.95 after talks reportedly broke down with potential potential buyer Novartis AG (ADR) (NYSE:NVS).  Shares of the biopharmaceutical company have more than doubled since the end of October on speculation of a deal, and on Wednesday the stock closed at $101.63 on speculation that a deal would go through.

CYTK Financial details

Company Rating
Sell
Market Cap
6.94B
Income
-524.4M
Revenue
7.53M
Book val./share
-3.9
Cash/share
6.21
Dividend
-
Dividend %
-
Employees
423
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-18.88
Forward P/E
-21.91
PEG
-8.9
P/S
1279.4
P/B
-22.33
P/C
11.29
P/FCF
-28.85
Quick Ratio
6.97
Current Ratio
7.22
Debt / Equity
-1.64
LT Debt / Equity
-1.57
-
-
EPS (TTM)
-5.43
EPS next Y
-3.2
EPS next Q
-1.14
EPS this Y
21.65%
EPS next Y
-41.08%
EPS next 5Y
-212.45%
EPS last 5Y
16.04%
Revenue last 5Y
-22.46%
Revenue Q/Q
342.33%
EPS Q/Q
2.22%
-
-
-
-
SMA20
-10.61%
SMA50
-25.68%
SMA100
103.43%
Inst Own
79.42%
Inst Trans
0.7%
ROA
-70%
ROE
187%
ROC
-0.75%
Gross Margin
-3997%
Oper. Margin
-6344%
Profit Margin
-6641%
Payout
-
Shs Outstand
103.01M
Shs Float
99.23M
-
-
-
-
Target Price
60.71
52W Range
25.98-110.25
52W High
-36.26%
52W Low
+180.44%
RSI
51.02
Rel Volume
0.4
Avg Volume
4.02M
Volume
1.61M
Perf Week
3.73%
Perf Month
-8.35%
Perf Quarter
155.22%
Perf Half Y
133.7%
-
-
-
-
Beta
0.694
-
-
Volatility
1.91%, 5.26%
Prev Close
-1.82%
Price
70.11
Change
-1.81%

CYTK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.470.870.921.050.08
Net income per share
-2.59-2.54-3.15-4.48-5.45
Operating cash flow per share
-1.580.14-1.85-3.33-4.29
Free cash flow per share
-1.62-0.03-2.49-3.46-4.31
Cash per share
3.917.196.138.716.37
Book value per share
-0.191.763.17-1.2-4
Tangible book value per share
-0.191.763.17-1.2-4
Share holders equity per share
-0.191.763.17-1.2-4
Interest debt per share
2.842.753.898.917.18
Market cap
610.87M1.34B3.5B4.12B8.06B
Enterprise value
710.51M1.4B3.66B4.8B8.7B
P/E ratio
-4.1-8.17-14.46-10.22-15.31
Price to sales ratio
22.7424.0249.7643.511.07K
POCF ratio
-6.72149.93-24.59-13.74-19.45
PFCF ratio
-6.53-635.76-18.31-13.24-19.38
P/B Ratio
-55.8511.8314.37-38.14-20.86
PTB ratio
-55.8511.8314.37-38.14-20.86
EV to sales
26.4425.0251.9950.741.16K
Enterprise value over EBITDA
-7.64-15.76-19.69-15.34-17.97
EV to operating cash flow
-7.82156.18-25.69-16.02-21
EV to free cash flow
-7.6-662.29-19.13-15.44-20.93
Earnings yield
-0.24-0.12-0.07-0.1-0.07
Free cash flow yield
-0.150-0.05-0.08-0.05
Debt to equity
-12.441.231.11-6.94-1.64
Debt to assets
0.470.260.320.740.77
Net debt to EBITDA
-1.07-0.63-0.85-2.19-1.33
Current ratio
8.9815.27.459.46.12
Interest coverage
-3.61-2.43-6.35-6.34-8.6
Income quality
0.75-0.070.660.770.79
Dividend Yield
00000
Payout ratio
0000-0.04
Sales general and administrative to revenue
1.470.951.371.8823.06
Research and developement to revenue
3.211.742.270.0742.26
Intangibles to total assets
00000
Capex to operating cash flow
0.03-1.240.340.040
Capex to revenue
-0.1-0.2-0.69-0.12-0.19
Capex to depreciation
-2.03-6.04-21.47-1.95-0.12
Stock based compensation to revenue
0.40.320.380.519.57
Graham number
3.3310.031511.0122.16
ROIC
-0.92-0.47-0.33-0.43-1.34
Return on tangible assets
-0.51-0.31-0.29-0.4-0.64
Graham Net
-1.250.69-1.47-3.79-6.16
Working capital
207.73M443.02M463.81M710.57M525.37M
Tangible asset value
-10.94M113.38M243.86M-107.9M-386.32M
Net current asset value
-67M53.8M-61.78M-327.49M-582.59M
Invested capital
-12.441.231.11-6.94-1.64
Average receivables
5.97M4.79M28.12M25.98M715K
Average payables
5.96M8.11M14.57M23.35M23.56M
Average inventory
-3.39M-2.21M-28.12M-25.98M-73.5K
Days sales outstanding
70.1428.9268.560.5762.19
Days payables outstanding
34.5830.3148.1238.82660.11
Days of inventory on hand
0-16.64-118.26-0.220
Receivables turnover
5.212.631.36643.465.87
Payables turnover
10.5512.047.589.40.55
Inventory turnover
0-21.93-3.09-1.64K0
ROE
13.63-1.45-0.993.731.36
Capex per share
-0.05-0.17-0.64-0.13-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.020.050.0100.02
Net income per share
-1.39-1.36-1.34-1.35-1.38
Operating cash flow per share
-1.04-1.29-1.27-1-0.75
Free cash flow per share
-1.07-1.29-1.28-1-0.75
Cash per share
8.286.985.915.616.21
Book value per share
-1.14-2.41-3.48-4.57-3.9
Tangible book value per share
-1.14-2.41-3.48-4.57-3.9
Share holders equity per share
-1.14-2.41-3.48-4.57-3.9
Interest debt per share
8.18.027.967.946.59
Market cap
4.33B3.35B3.12B2.83B8.27B
Enterprise value
5.02B4B3.8B3.48B8.91B
P/E ratio
-8.24-6.47-6.07-5.47-15.1
Price to sales ratio
2.21K725.953.6K7.49K4.95K
POCF ratio
-44.11-27.39-25.64-29.42-111.72
PFCF ratio
-42.72-27.3-25.49-29.35-111.6
P/B Ratio
-40.14-14.62-9.38-6.45-21.41
PTB ratio
-40.14-14.62-9.38-6.45-21.41
EV to sales
2.56K866.564.39K9.2K5.33K
Enterprise value over EBITDA
-41.41-33.86-33-30.14-73.61
EV to operating cash flow
-51.08-32.69-31.23-36.16-120.39
EV to free cash flow
-49.46-32.58-31.05-36.08-120.27
Earnings yield
-0.03-0.04-0.04-0.05-0.02
Free cash flow yield
-0.02-0.04-0.04-0.03-0.01
Debt to equity
-6.94-3.28-2.25-1.71-1.64
Debt to assets
0.740.840.961.010.77
Net debt to EBITDA
-5.65-5.49-5.91-5.62-5.31
Current ratio
9.49.058.947.226.12
Interest coverage
-7.81-9.4-9.13-8.74-7.47
Income quality
0.710.930.950.740.54
Dividend Yield
00000
Payout ratio
0-0.03000
Sales general and administrative to revenue
27.5810.7745.82106.1126.38
Research and developement to revenue
3.370.461147.03
Intangibles to total assets
00000
Capex to operating cash flow
0.0300.0100
Capex to revenue
-1.64-0.09-0.83-0.58-0.05
Capex to depreciation
-1.93-0.22-0.39-0.12-0.01
Stock based compensation to revenue
6.93.2921.5349.5111.65
Graham number
5.988.5810.2511.7711.01
ROIC
-0.16-0.19-0.22-0.27-0.34
Return on tangible assets
-0.13-0.15-0.16-0.17-0.17
Graham Net
-3.6-4.78-5.71-6.66-6
Working capital
710.57M605.41M520.96M483.69M525.37M
Tangible asset value
-107.9M-229.02M-333.12M-438.8M-386.32M
Net current asset value
-327.49M-438.21M-526.44M-618M-582.59M
Invested capital
-6.94-3.28-2.25-1.71-1.64
Average receivables
1.22M576.5K995.5K1.74M1.89M
Average payables
20.02M21.48M14.96M13.18M17.65M
Average inventory
-73.5K-576.5K-995.5K-1.74M-1.25M
Days sales outstanding
6.7619.63102.2559569.06
Days payables outstanding
30.7319.6713.5915.04305.55
Days of inventory on hand
-0.18-1.14-1.07-2.730
Receivables turnover
13.314.590.880.151.3
Payables turnover
2.934.586.625.980.29
Inventory turnover
-510.33-78.95-84.46-33.030
ROE
1.220.570.390.290.35
Capex per share
-0.030-0.0100

CYTK Frequently Asked Questions

What is Cytokinetics, Incorporated stock symbol ?

Cytokinetics, Incorporated is a US stock , located in South san francisco of Ca and trading under the symbol CYTK

Is Cytokinetics, Incorporated buy or a sell ?

8 stock analysts have 8 predictions with a medium analyst target price of $59.88. The lowest prediction is $45 and the highest is $75

What is CYTK stock prediction ?

What is Cytokinetics, Incorporated stock quote today ?

Cytokinetics, Incorporated stock price is $70.11 today.

Is Cytokinetics, Incorporated stock public?

Yes, Cytokinetics, Incorporated is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap